Background: The single nucleotide polymorphism 5p12-rs10941679has been found to be
, Gianluca Severi 8, 3 , Rebecca Hein ).
Conclusion: 5p12 is a breast cancer susceptibility locus for PR-positive, lower gradebreast cancer.
Impact: Multi-centre fine-mapping studies of this region are needed as a first step to identifying the causal variant or variants. ; Pheterogeneity=0.004) (5) . In addition, our previous breast cancer GWAS reported evidence of an association with another SNP on 5p12, rs981782 (P=9x10 -6 ), based on data from 23,408 cases and 24,636 controls from 21 BCAC studies (2) . The Icelandic-led study evaluated both these SNPs in multivariable models and observed that only 5p12-rs10941679 was independently associated with breast cancer risk (5). This SNP was not among those genotyped in the first phase of our previous GWAS (2).
The aims of the present study were to estimate the relative risk of breast cancer associated with 5p12-rs10941679 in a much larger case-control series comprising studies participating in the BCAC, to evaluate its independence of any association with 5p12-rs981782, and to assess associations by disease subtypes defined by histopathology. 
Materials and Methods
Thirty-seven studies from Europe, North America, Australia, and Asia participated in genotyping for the present study via the BCAC, contributing a total of 41,243 invasive breast cancer cases, 1,406 cases of ductal carcinoma in-situ (DCIS) and 46,621 controls of white European origin and 3,082 invasive cases and 2,402 controls of Asian origin. All 37 studies genotyped 5p12-rs10941679. Seven studies also genotyped 5p12-rs981782 in a total of 8,247
invasive cases and 10,363 controls, all of European origin. Fourteen of the 37 participating studies had already genotyped 5p12-rs981782 in white Europeans as part of the previously published study (2) . Descriptions of studies are provided in Supplemental Table 1 and final sample sizes are presented in Supplemental Table 2 .
All studies provided information on disease status and self-reported race/ethnicity for all subjects and age at diagnosis for cases. All but five studies (BIGGS, FBCS, HUBCS, RBCS and UCIBCS) also provided age at data collection for controls. "Selected cases" were a subset of 7,128 invasive cases selected for inclusion or oversampled by nine studies because they had bilateral breast cancer, a family history of breast cancer and/or other characteristics that suggested they were at increased genetic risk (all cases from BBCS, FBCS, GC-HBOC, kConFab/AOCS, MBCSG, NC-BCFR, OFBCR and RBCS and 211 cases from CNIO-BCS, see Supplemental Table 1 ). ER and progesterone receptor (PR) status were provided for a subset of cases, respectively, as were human epidermal growth factor receptor 2 (HER2) status and other histological features including axillary node status and tumor grade, size, and morphology (see Supplemental Table 3 ). This histopathology information was generally abstracted from medical reports. Subjects who reported having ethnicity other than white European were excluded, with the exception of those from the three Asian studies, for which only subjects of Asian origin were included. Only subjects from studies that genotyped at least 30 cases of DCIS were included in the analyses of risk of DCIS. All subjects gave written informed consent, where applicable, and each study was approved by the relevant local institutional review boards.
Most studies carried out genotyping using Taqman 
Statistical Methods
Departure from Hardy-Weinberg equilibrium (HWE) was tested for in controls from each centre using Pearson´s Χ 2 test (1df). The association of each SNP with breast cancer risk was assessed by estimating genotype-specific and per-allele ORs using logistic regression, adjusted for study.
The exclusion of studies for which the age of controls was not known and the additional adjustment for age (in 5-year categories and as a continuous covariate) made no substantial difference to the results. Between-study heterogeneity in ORs was assessed using a likelihood and age (<40, 40-49, 50-59, 60-69, ≥70 years) were evaluated using a similar LRT, the latter modeled as a linear trend by fitting the median age for each of the defined categories.
ORs specific to disease subtypes defined by ER, PR and HER2 status (positive, negative), by combinations of these markers, and by axillary node status (none, ≥1 affected), tumor grade (1, 2, ≥3), tumor size (≤10, 11-20, >20mm) and tumor morphology (ductal, lobular), were estimated for white Europeans using polytomous logistic regression with control status as the reference outcome. Heterogeneity in the OR by subtypes was tested for by applying polytomous logistic regression to cases-only, treating the number of minor alleles as the outcome and restricting, for each explanatory variable, the beta coefficient for the comparison of 2 to 0 minor alleles to be double that for the comparison of 1 to 0 minor alleles. This is equivalent to modeling a log-additive per-allele OR and allows multiple tumor markers to be modeled simultaneously. Linear trends were tested for grade by fitting values 1, 2, and 3, and for size by fitting the median value, for the defined categories, respectively. Enrichment of the risk allele in "selected cases" was assessed using the likelihood ratio test comparing polytomous logistic regression models with and without the per-allele OR constrained to be equal for selected and unselected cases, relative to controls (1df). We minimised bias in the estimation of OR by repeating all analyses after excluding "selected cases". All statistical tests were two-sided. The term "genome-wide" statistically significant is taken to imply p<10 -7 ; otherwise "statistically significant" implies p<0.05. All analyses were carried out using Stata: Release 10 (6).
Meta-analyses were carried out using metan command based on log-transformed OR estimates and their 95%CI from different reports. 
Results
Minimum genotype concordance of 98% for duplicate samples and 95% for the CEPH samples was observed in all studies, as were minimum genotype calls of 97% for both SNPs in cases and controls. Evidence of departure from HWE was observed for 5p12-rs10941679 in controls from two studies (FBCS [P = 0.02] and HABCS [P=0.005], Supplemental Table 2) ; for both studies, cluster plots were double-checked visually and determined to be of high quality, and all their genotype data were therefore included in the final analysis.
Thirty-four studies successfully genotyped 5p12-rs10941679 in a total of 40,972 invasive breast cancer cases (7,037 of which were selected for increased genetic risk), 1,398 DCIS cases, and 46,334 controls of white European origin. Genotypes were also obtained for this SNP for 3,007 cases and 2,337 controls of Asian origin recruited by three studies. A total of 8,213
invasive cases and 10,340 controls were successfully genotyped for 5p12-rs981782 by seven studies. Previously published data for this SNP were included from 14 studies to obtain genotypes for both SNPs in 5p12 for 23,548 invasive cases and 28,142 controls, all of white European origin. Genotype counts by study are provided in Supplemental Table 4 .
The minor G allele of 5p12-rs10941679 was less frequent in white European women (26%) than in Asian women (49%). Estimated ORs, for invasive breast cancer and DCIS, and by ethnicity, are presented in Table 1 . The genotype-specific OR estimates were consistent with a log-additive model for white Europeans. The per-G-allele OR estimate was 1.12 (95%CI=1.10- respectively. This trend was also observed when age was modeled in years (P=0.02), with an estimated interaction OR of 1.02 (95%CI=1.00-1.04) per G allele, per 10-year increase in age.
The same trend was observed after excluding "selected cases" (interaction OR=1.02,
95%CI=1.00-1.05, P=0.03).
Results from analyses by breast cancer subtypes defined by histopathological features are presented in Tables 2 and 3 . The number of cases from each study for which this information was available is presented in Supplemental Table 3 . We observed strong evidence that the perallele OR associated with 5p12-rs10941679 differed by ER status, PR status and ER/PR combined (all P<10 -5 , Table 2 ). When ER and PR status were modeled together in the case-only analysis only the association with PR status was maintained (P=6x10 There was also clear evidence that 5p12-rs10941679 was more strongly associated with the risk of lower-grade breast cancer (P=5x10 -7 , Table 3 ). When grade and PR status were modeled together in a case-only analysis, evidence of heterogeneity was observed for both tumor characteristics (P<0.002). After excluding "selected cases", the per-G-allele OR estimates were 
Discussion
This analysis of 40,972 invasive cases and 46,334 controls from 37 studies definitively confirms the 5p12-rs10941679 as a breast cancer susceptibility locus in white European women.
After excluding cases selected for increased genetic susceptibility, we estimated an OR for white European women of 1.11 per G allele (95%CI=1.08-1.14). This association was independent of a possible association with 5p12-rs981782 and appeared to be stronger for older women. 
per-G-allele OR of 1.07 (95%CI=0.99-1.15) using data from 2,950 cases and 2,986 controls (7).
Assessed together, these two large studies suggest that 5p12-rs10941679 is associated with increased breast cancer risk in Asian women (meta-analysis OR=1.07 (95%CI=1.02-1.13, P=0.01), although even larger studies will be required to precisely estimate the corresponding OR.
The initial paper on 5p12-rs10941679, based on 6,145 cases and 33,016 controls, reported a larger per-G-allele OR for breast cancer in general of 1.19 (95%CI=1.11-1.28) (5).
This larger initial estimate probably reflects "winner's curse" whereby the estimated OR in the study discovering the association tends to be overestimated (8). Stacey et al. (5) also reported that the increased risk associated with 5p12-rs10941679 was limited to ER-positive disease and consistent results have been observed in other studies (7, 9) . We replicated this finding, but our larger sample size enabled us to carry out a more detailed analysis that revealed a stronger association with PR-positive disease (per-G-allele OR=1.16, 95%CI=1.12-1.20). The heterogeneity in the OR by ER status appeared to be driven by the correlation between ER and PR status. Furthermore, we have established that the association is also stronger for lower grade tumors in general, and lower grade PR-positive tumors specifically. Stacey et al. (5), also noted a possibly larger OR for lower grade tumors, but not after ER-status was taken into account. This multifaceted heterogeneity has also been observed for 10q26-rs2981582, which appears to be associated with increased risk of lower grade ER-positive tumors (10).
In our previous GWAS, we observed that the minor G allele of 5p12-rs981782 in the same region was associated with reduced risk of breast cancer. The estimated per-G-allele OR for white European women was 0.94 (95%CI=0.91-0.97, P=9x10 It is less clear whether the association between 5p12-rs981782 and breast cancer risk is independent of the effect marked by 5p12-rs10941679. In contrast to the findings of Stacey et al. (5) , in the present study (23,548 cases and 28,142 controls) the evidence of association for 5p12-rs981782 remained after adjusting for 5p12-rs10941679 (P=0.007), although the effect was slightly attenuated. Furthermore, the correlation between these two SNPs was too weak (r 2 =0.04, N=52,506) for the association seen with 5p12-r981782 to be due to confounding by 5p12-rs10941679. However, it remains possible that these two associations are driven by a variant correlated with both SNPs. Stacey et al. (5) found that a third SNP nearby, 5p12-rs4415084 was associated with breast cancer risk, independently of 5p12-rs10941679 (r 2 =0.51 between the two SNPs). Multi-centre fine-mapping studies of this region are needed to obtain the samples sizes required to identify the causal variant or variants behind these multiple small signals.
As discussed by Stacey et al. (5), 5p12-rs10941679 resides between two genes: MRPS30, which encodes the smaller 28S subunit of the mitochondrial ribosome and has pro-apoptotic properties (12) , and FGF10, a fibroblast growth factor which is amplified in around 10% of breast cancers (13) , although there is a recombination hotspot separating this SNP from FGF10. Therefore, as for the vast majority of low-penetrance breast cancer susceptibility loci identified by GWAS, an implicated gene or functional mechanism remains to be elucidated.
A potential limitation of our study was that information on tumor histopathology was not available for all cases and, where it was, these data were predominantly abstracted from medical records, rather than being obtained through a standardised pathology review. Thus some misclassification may have been present and this may have attenuated some associations with tumor phenotype. However the strong association with PR and ER status suggests that this effect was minimal, at least for the features examined here. 
